Gastroesophageal Junction Adenocarcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: GST012 MIFTS: 42	Gastroesophageal Junction Adenocarcinoma Categories: Cancer diseases, Cardiovascular diseases, Gastrointestinal diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Gastroesophageal Junction Adenocarcinoma

MalaCards integrated aliases for Gastroesophageal Junction Adenocarcinoma:

Name: Gastroesophageal Junction Adenocarcinoma ¹² ¹⁵

Adenocarcinoma of the Gastroesophageal Junction ⁷³

Adenocarcinoma of Cardioesophageal Junction ¹²

Adenocarcinoma of Gastroesophageal Junction ¹²

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Gastrointestinal diseases Cardiovascular diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:4944

NCIt ⁵⁰ C9296

UMLS ⁷³ C1332166

Sources

Summaries for Gastroesophageal Junction Adenocarcinoma

MalaCards based summary : Gastroesophageal Junction Adenocarcinoma, also known as adenocarcinoma of the gastroesophageal junction, is related to adenocarcinoma and helicobacter pylori infection, and has symptoms including abdominal pain An important gene associated with Gastroesophageal Junction Adenocarcinoma is ERBB2 (Erb-B2 Receptor Tyrosine Kinase 2), and among its related pathways/superpathways are Dendritic Cells Developmental Lineage Pathway and Adherens junction. The drugs Herceptin and Capecitabine have been mentioned in the context of this disorder. Affiliated tissues include endothelial, lymph node and lung, and related phenotype is digestive/alimentary.

Sources

Related Diseases for Gastroesophageal Junction Adenocarcinoma

Diseases related to Gastroesophageal Junction Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 51)

#	Related Disease	Score	Top Affiliating Genes
1	adenocarcinoma	10.9
2	helicobacter pylori infection	10.1
3	cercarial dermatitis	10.0	IL1B SNAI1
4	exanthem	10.0	ERBB2 TLR9
5	uterine anomalies	10.0	ERBB2 TLR9
6	adenosquamous carcinoma	10.0
7	degos 'en cocarde' erythrokeratoderma	10.0
8	lymphomatous meningitis	10.0
9	female reproductive system disease	9.9	ERBB2 TLR9
10	reproductive system disease	9.9	ERBB2 TLR9
11	parasitic helminthiasis infectious disease	9.9	SNAI1 TLR9
12	respiratory system cancer	9.9	ERBB2 TLR9
13	suppurative otitis media	9.9	IL1B TLR9
14	central nervous system vasculitis	9.9	IL1B TLR9
15	middle ear disease	9.9	IL1B TLR9
16	lacrimal apparatus disease	9.9	IL1B TLR9
17	perinatal necrotizing enterocolitis	9.9	IL1B TLR9
18	extrinsic cardiomyopathy	9.9	IL1B TLR9
19	lymph node disease	9.9	IL1B TLR9
20	keratitis, hereditary	9.9	IL1B TLR9
21	tonsillitis	9.9	IL1B TLR9
22	parasitic protozoa infectious disease	9.9	IL1B TLR9
23	placenta disease	9.9	IL1B TLR9
24	autoimmune disease of central nervous system	9.9	IL1B TLR9
25	bacterial meningitis	9.9	IL1B TLR9
26	meningitis	9.9	IL1B TLR9
27	upper respiratory tract disease	9.9	IL1B TLR9
28	primary bacterial infectious disease	9.9	IL1B TLR9
29	bacterial infectious disease	9.9	IL1B TLR9
30	autoimmune disease of the nervous system	9.9	IL1B TLR9
31	bronchial disease	9.9	IL1B TLR9
32	bone inflammation disease	9.9	IL1B TLR9
33	oral cavity cancer	9.9	ERBB2 TLR9
34	toxoplasmosis	9.9	IL1B TLR9
35	arteries, anomalies of	9.9	IL1B TLR9
36	glucose metabolism disease	9.9	IL1B TLR9
37	trypanosomiasis	9.8	IL1B TLR9
38	immune system disease	9.8	IL1B TLR9
39	intestinal disease	9.8	IL1B TLR9
40	endocrine gland cancer	9.8	ERBB2 TLR9
41	acquired metabolic disease	9.8	IL1B TLR9
42	mouth disease	9.8	IL1B TLR9
43	periodontitis	9.8	IL1B TLR9
44	gastrointestinal system cancer	9.8	ERBB2 SNAI1 TLR9
45	respiratory system disease	9.8	IL1B TLR9
46	keratoconjunctivitis sicca	9.8	ERBB2 IL1B TLR9
47	stomach disease	9.8	ERBB2 IL1B TLR9
48	gastrointestinal system disease	9.8	ERBB2 IL1B TLR9
49	rheumatic disease	9.7	IL1B TLR9
50	chronic granulomatous disease	9.6	IL1B TLR9

Graphical network of the top 20 diseases related to Gastroesophageal Junction Adenocarcinoma:

Sources

Symptoms & Phenotypes for Gastroesophageal Junction Adenocarcinoma

UMLS symptoms related to Gastroesophageal Junction Adenocarcinoma:

abdominal pain

MGI Mouse Phenotypes related to Gastroesophageal Junction Adenocarcinoma:

⁴⁶

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	digestive/alimentary	MP:0005381	8.92	ERBB2 GUCY2C SNAI1 TLR9

Sources

Drugs & Therapeutics for Gastroesophageal Junction Adenocarcinoma

FDA approved drugs:

#	Drug Name	Active Ingredient(s) ¹⁸	Company	Approval Date
1	Herceptin ¹⁸ ⁴⁹	TRASTUZUMAB	Genentech	October 1998
FDA Label: Herceptin Disease/s that Drug Treats:Breast cancer/gastric cancer Indications and Usage: ¹⁸ Herceptin is a HER2/neu receptor antagonist indicated for: the treatment of HER2 overexpressing breast cancer (1.1, 1.2). the treatment of HER2-overexpressing metastatic gastric orgastroesophageal junction adenocarcinoma (1.3) DrugBank Targets: ¹⁶ 1. Receptor tyrosine-protein kinase erbB-2;2. Epidermal growth factor receptor;3. Complement C1r subcomponent;4. Complement C1q subcomponent subunit A;5. Complement C1q subcomponent subunit B;6. Complement C1q subcomponent subunit C;7. Complement C1s subcomponent;8. High affinity immunoglobulin gamma Fc receptor I;9. Low affinity immunoglobulin gamma Fc region receptor II-a;10. Low affinity immunoglobulin gamma Fc region receptor II-b;11. Low affinity immunoglobulin gamma Fc region receptor II-c;12. Low affinity immunoglobulin gamma Fc region receptor III-B;13. Low affinity immunoglobulin gamma Fc region receptor III-A Mechanism of Action: ¹⁸ Target: human epidermal growth factor receptor 2 protein (HER2) Action: binds with strong affinity for immune response FDA: The HER2 (or c-erbB2) proto-oncogene encodes a transmembrane receptor protein of 185 kDa, which is structurally related to the epidermal growth factor receptor. Herceptin has been shown, in both in vitro assays and in animals, to inhibit the proliferation of human tumor cells that overexpress HER2. Herceptin is a mediator of antibody-dependent cellular cytotoxicity (ADCC). In vitro, Herceptin-mediated ADCC has been shown to be preferentially exerted on HER2 overexpressing cancer cells compared with cancer cells that do not overexpress HER2.

Drugs for Gastroesophageal Junction Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 132)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Capecitabine

Approved, Investigational

Phase 2, Phase 3,Phase 3,Phase 1

154361-50-9

60953

Oxaliplatin

Approved, Investigational

Phase 2, Phase 3,Phase 3,Phase 1

61825-94-3

43805 6857599 5310940 9887054

Docetaxel

Approved, Investigational

Phase 2, Phase 3,Phase 3,Phase 1

114977-28-5

148124

Bevacizumab

Approved, Investigational

Phase 2, Phase 3

216974-75-3

Cisplatin

Approved

Phase 2, Phase 3,Phase 3,Phase 1,Early Phase 1

15663-27-1

2767 441203 84093

Epirubicin

Approved

Phase 2, Phase 3,Phase 3,Early Phase 1

56420-45-2

41867

leucovorin

Approved

Phase 3,Phase 2,Phase 1

58-05-9

6006 143

Levoleucovorin

Approved, Investigational

Phase 3,Phase 1,Phase 2

68538-85-2

Fluorouracil

Approved

Phase 3,Phase 2,Phase 1,Early Phase 1

51-21-8

3385

Paclitaxel

Approved, Vet_approved

Phase 3,Phase 2,Phase 1

33069-62-4

36314

Trastuzumab

Approved, Investigational

Phase 3,Phase 2,Phase 1,Not Applicable

180288-69-1

9903

Ramucirumab

Approved, Investigational

Phase 3,Phase 2,Phase 1

947687-13-0

Irinotecan

Approved, Investigational

Phase 3,Phase 2,Phase 1

100286-90-6, 97682-44-5

60838

Gefitinib

Approved, Investigational

Phase 3

184475-35-2

123631

Cetuximab

Approved

Phase 3,Phase 2

205923-56-4

56842117 2333

Tegafur

Approved, Investigational

Phase 3,Phase 2,Phase 1

17902-23-7

5386

Pembrolizumab

Approved

Phase 3,Phase 2,Phase 1

1374853-91-4

Carboplatin

Approved

Phase 3,Phase 2,Phase 1

41575-94-4

10339178 38904 498142

Adenosine

Approved, Investigational

Phase 2, Phase 3

58-61-7

60961

Folic Acid

Approved, Nutraceutical, Vet_approved

Phase 3,Phase 2,Phase 1

59-30-3

6037

Lapatinib

Approved March 2007, Investigational

Phase 2, Phase 3,Phase 3,Phase 1

388082-78-8, 231277-92-2

208908 9941095

Antimetabolites

Phase 2, Phase 3,Phase 3,Phase 1,Early Phase 1

Antimetabolites, Antineoplastic

Phase 2, Phase 3,Phase 3,Phase 1,Early Phase 1

Antimitotic Agents

Phase 2, Phase 3,Phase 3,Phase 1

Angiogenesis Modulating Agents

Phase 2, Phase 3

Topoisomerase Inhibitors

Phase 2, Phase 3,Phase 3,Phase 1,Early Phase 1

Antibiotics, Antitubercular

Phase 2, Phase 3,Phase 3,Phase 1,Early Phase 1

Anti-Bacterial Agents

Phase 2, Phase 3,Phase 3,Phase 1,Early Phase 1

Protein Kinase Inhibitors

Phase 2, Phase 3,Phase 3,Phase 1

Angiogenesis Inhibitors

Phase 2, Phase 3

s 1 (combination)

Phase 3,Phase 2,Phase 1

Immunoglobulins

Phase 3,Phase 2,Phase 1

Antibodies, Monoclonal

Phase 3,Phase 2,Phase 1

Antibodies

Phase 3,Phase 2,Phase 1

Mitogens

Phase 3,Phase 2,Phase 1

Vitamin B9

Phase 3,Phase 2,Phase 1

Immunologic Factors

Phase 3,Phase 2,Phase 1,Early Phase 1

Immunosuppressive Agents

Phase 3,Phase 2,Phase 1,Early Phase 1

Antineoplastic Agents, Phytogenic

Phase 3,Phase 2,Phase 1

Folate

Phase 3,Phase 2,Phase 1

Albumin-Bound Paclitaxel

Phase 3,Phase 2,Phase 1

Appetite Stimulants

Phase 3

Antiemetics

Phase 3

Central Nervous System Stimulants

Phase 3

Analgesics

Phase 3,Phase 1

Endothelial Growth Factors

Phase 3,Phase 1

Opiate Alkaloids

Phase 3

topoisomerase I inhibitors

Phase 3,Phase 2,Phase 1

Pharmaceutical Solutions

Phase 3,Phase 2,Phase 1

Nucleic Acid Synthesis Inhibitors

Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 197)

#	Name	Status	NCT ID	Phase	Drugs
1	Preoperative Concurrent Chemoradiotherapy for Potentially Resectable Adenocarcinoma of the Esophagogastric Junction	Unknown status	NCT01962246	Phase 2, Phase 3	Oxaliplatin; Capecitabine
2	Comparison Study of Brachytherapy and Endoscopic Stenting for Dysphagia in Esophago-Gastric Junction Cancer	Unknown status	NCT01786278	Phase 2, Phase 3
3	A Study of Apatinib Versus Docetaxol Patients With Advanced Gastric Cancer	Unknown status	NCT02409199	Phase 2, Phase 3	Docetaxel;apatinib
4	Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric Cancer	Unknown status	NCT00450203	Phase 2, Phase 3	capecitabine;cisplatin;Epirubicin;Lapatinib
5	S-1+Oxaliplatin vs.S-1+Cisplatin First-line Treatment of Advanced or Recurrent Non-intestinal Type Gastric Adenocarcinoma Patients	Completed	NCT01824459	Phase 3	S-1;Oxaliplatin;Cisplatin
6	Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma	Completed	NCT00917384	Phase 3	Placebo
7	Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach	Completed	NCT01640782	Phase 3	Irinotecan, Leucovorin, 5-Fluorouracil, Docetaxel, Cisplatin;Leucovorin, 5-Fluorouracil
8	Gefitinib in Treating Patients With Esophageal Cancer That is Progressing After Chemotherapy	Completed	NCT01243398	Phase 3
9	Radiation Therapy and Chemotherapy, With or Without Cetuximab, Followed by Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery	Completed	NCT01107639	Phase 3	cisplatin;docetaxel
10	Erbitux in Combination With Xeloda and Cisplatin in Advanced Esophago-gastric Cancer	Completed	NCT00678535	Phase 3	Cetuximab;Capecitabine;Cisplatin
11	A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma	Completed	NCT01170663	Phase 3	Placebo;Paclitaxel
12	Symptom Control With or Without Docetaxel in Treating Patients With Relapsed Esophageal Cancer or Stomach Cancer	Completed	NCT00978549	Phase 3	docetaxel;steroid therapy
13	Efficacy and Safety Study of the Combined Modality Therapy in Adenocarcinoma of the Esophago-gastric Junction	Recruiting	NCT01523015	Phase 2, Phase 3
14	Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma	Recruiting	NCT03777657	Phase 3	Tislelizumab (BGB-A317) combined with oxaliplatin and capecitabine or Tislelizumab (BGB-A317) combined with Cisplatin and 5-FU;Placebo combined with oxaliplatin and capecitabine or Placebo combined with Cisplatin and 5-FU
15	Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)	Recruiting	NCT03615326	Phase 3	Cisplatin;5-FU;Oxaliplatin;Capecitabine;S-1
16	A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer	Recruiting	NCT02898077	Phase 3	Ramucirumab;Paclitaxel;Placebo
17	Preoperative Concurrent Chemoradiotherapy for Locally Advanced Gastroesophageal Junction or Upper Gastric Adenocarcinoma	Recruiting	NCT02193594	Phase 2, Phase 3	Adjuvant chemotherapy
18	Radical Gastrectomy With/Without HIPEC in Advanced Gastric Cancer Patients	Recruiting	NCT02381847	Phase 3
19	Adjuvant Capecitabine Versus Observation Alone in Curatively Resected Stage IB Gastric Cancer((KCSG ST14-05)	Recruiting	NCT01917552	Phase 3	capecitabine
20	Cytoreductive Surgery (CRS) With/Without HIPEC in Gastric Cancer With Peritoneal Carcinomatosis	Recruiting	NCT02158988	Phase 3
21	Perioperative Chemotherapy Compared To Neoadjuvant Chemoradiation in Patients With Adenocarcinoma of the Esophagus	Recruiting	NCT02509286	Phase 3	5-Fluorouracil;Leucovorin;Oxaliplatin;Docetaxel;Carboplatin;Paclitaxel
22	A Phase 3 Efficacy, Safety and Tolerability Study of Zolbetuximab (Experimental Drug) Plus mFOLFOX6 Chemotherapy Compared to Placebo Plus mFOLFOX6 as Treatment for Gastric and Gastroesophageal Junction Gastroesophageal (GEJ) Cancer	Recruiting	NCT03504397	Phase 3	zolbetuximab;placebo;oxaliplatin;leucovorin;fluorouracil
23	A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061)	Active, not recruiting	NCT02370498	Phase 3	paclitaxel
24	Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063)	Active, not recruiting	NCT03019588	Phase 3	Paclitaxel
25	Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)	Active, not recruiting	NCT02625623	Phase 3	Avelumab;Irinotecan;Paclitaxel
26	Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma	Active, not recruiting	NCT02545504	Phase 3	Andecaliximab;Placebo;Leucovorin;5-fluorouracil;Oxaliplatin
27	A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer	Active, not recruiting	NCT02314117	Phase 3	Ramucirumab;Capecitabine;Cisplatin;Placebo;Fluorouracil
28	A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer	Active, not recruiting	NCT02178956	Phase 3	BBI608;Paclitaxel
29	Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062)	Active, not recruiting	NCT02494583	Phase 3	cisplatin;5-FU;capecitabine
30	LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib	Active, not recruiting	NCT00680901	Phase 3	Lapatinib;Placebo;Capecitabine;Oxaliplatin
31	Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)	Active, not recruiting	NCT02564263	Phase 3	paclitaxel;docetaxel;irinotecan
32	Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer	Active, not recruiting	NCT01196390	Phase 3	Carboplatin;Paclitaxel
33	A Study of CS1001 in Subjects With Unresectable Locally Advanced or Metastatic Gastric Adenocarcinoma (GC) or Gastro-Esophageal Junction (GEJ) Adenocarcinoma	Not yet recruiting	NCT03802591	Phase 3	CS1001 monoclonal antibody;CS1001 placebo;Oxaliplatin;Capecitabine
34	A Randomized Phase III Study Comparing POF (Paclitaxel/Oxaliplatin/Leucovorin/5-FU) With S-1 Plus Docetaxel as a Postoperative Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer	Not yet recruiting	NCT03788226	Phase 3	POF;Docetaxel/S-1
35	Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer	Not yet recruiting	NCT03801876	Phase 3	Carboplatin;Paclitaxel
36	A Phase 3 Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as First-line Therapy in Gastric Cancer	Terminated	NCT02137343	Phase 3	Rilotumumab;Placebo;Cisplatin;Capecitabine
37	A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer	Terminated	NCT01450696	Phase 3	Capecitabine;Cisplatin;Herceptin
38	First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma	Terminated	NCT01697072	Phase 3	Rilotumumab;Epirubicin;Cisplatin;Capecitabine
39	A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer	Terminated	NCT01641939	Phase 2, Phase 3	Taxane;trastuzumab emtansine;trastuzumab emtansine
40	Raltitrexed and Paclitaxel for Gastric or Gastroesophageal Junction Adenocarcinoma	Unknown status	NCT03083613	Phase 2	Raltitrexed;Paclitaxel
41	Efficacy and Safety of Panitumumab Combined With Docetaxel and Cisplatin as a First-line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma	Unknown status	NCT01379807	Phase 2	panitumumab + docetaxel + cisplatino
42	Phase II Study of Neoadjuvant Taxotere, Cisplatin, and 5-Fluorouracil in Patients With Gastric or Gastroesophageal Junction Adenocarcinoma	Unknown status	NCT00763646	Phase 2	Taxotere, Cisplatin, and 5-FU
43	Apatinib in Combination With S-1 as First-Line Treatment in Patients With Advanced Gastric Cancer	Unknown status	NCT02525237	Phase 2	Apatinib;S-1
44	Docetaxel, Oxaliplatin, Capecitabine, Bevacizumab and Trastuzumab in Patients With Locally Advanced or Metastatic Gastric Cancer	Unknown status	NCT01359397	Phase 2	Docetaxel, Oxaliplatin, Capecitabin, Bevacizumab;Docetaxel, Oxaliplatin, Capecitabin, Bevacizumab, Trastuzumab
45	Study to Evaluate Safety and Efficacy of Perioperative Chemotherapy With Docetaxel, Cisplatin and Capecitabine (DCX) in Patients With Gastro-esophageal Cancer	Unknown status	NCT00865982	Phase 2	Docetaxel, Cisplatin, Capecitabine
46	Second-line Treatment With Icotinib in Esophageal Carcinoma Patients With EGFR Overexpression (IHC 3+) or Positive FISH	Unknown status	NCT01855854	Phase 2	Icotinib
47	Study of MBP-426 in Patients With Second Line Gastric, Gastroesophageal, or Esophageal Adenocarcinoma	Unknown status	NCT00964080	Phase 1, Phase 2	MBP-426/Leucovorin/5-FU
48	Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma	Completed	NCT00515411	Phase 2	Docetaxel, Leucovorin, Fluorouracil, Cisplatin;Docetaxel, Cisplatin, Fluorouracil, Neulasta, or Neupogen
49	Study of PEP02, Irinotecan or Docetaxel in Gastric or Gastroesophageal Junction Adenocarcinoma	Completed	NCT00813072	Phase 2	PEP02;irinotecan;docetaxel
50	Irinotecan, Cisplatin, and Bevacizumab in Treating Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma	Completed	NCT00084604	Phase 2	irinotecan hydrochloride;cisplatin

Search NIH Clinical Center for Gastroesophageal Junction Adenocarcinoma

Sources

Genetic Tests for Gastroesophageal Junction Adenocarcinoma

Sources

Anatomical Context for Gastroesophageal Junction Adenocarcinoma

MalaCards organs/tissues related to Gastroesophageal Junction Adenocarcinoma:

⁴¹

Endothelial, Lymph Node, Lung, Bone, Breast, Pancreas, Placenta

Sources

Publications for Gastroesophageal Junction Adenocarcinoma

Articles related to Gastroesophageal Junction Adenocarcinoma:

(show top 50) (show all 123)

#	Title	Authors	Year
1	Perioperative chemotherapy vs. neoadjuvant chemoradiation inA gastroesophageal junction adenocarcinoma : A population-based evaluation of the Munich Cancer Registry. ( 29071366 )	MA1nch S....Engel J.	2018
2	Evaluation of Expression of Human Epidermal Growth Factor Receptor 2 (HER2) in Gastric and Gastroesophageal Junction Adenocarcinoma Using IHC and Dual-ISH. ( 29277796 )	Dominguez C....Coppola D.	2018
3	Ramucirumab for the treatment of metastatic gastric or gastroesophageal junction adenocarcinoma following disease progression on first-line platinum- or fluoropyrimidine-containing combination therapy in Japanese patients: a phase 2, open-label study. ( 29508095 )	Yamaguchi K....Satoh T.	2018
4	Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma. ( 29094609 )	Joshi S.S....Catenacci D.V.	2018
5	Testicular Metastasis from Recurrent Gastroesophageal Junction Adenocarcinoma: Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Findings. ( 29430123 )		2018
6	Unusual case of left atrial myxoma with gastroesophageal junction adenocarcinoma. ( 29338297 )		2018
7	Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study. ( 29691300 )		2018
8	Combined taxane-based chemotherapy and intensity-modulated radiotherapy with simultaneous integrated boost for gastroesophageal junction adenocarcinoma. ( 29664354 )		2018
9	Personalized therapy based on image for esophageal or gastroesophageal junction adenocarcinoma. ( 29666803 )		2018
10	Immuno-Oncology Biomarkers for Gastric and Gastroesophageal Junction Adenocarcinoma: Why PD-L1 Testing May Not Be Enough. ( 29703766 )		2018
11	Neoadjuvant chemoradiotherapy or chemotherapy for gastroesophageal junction adenocarcinoma: A systematic review and meta-analysis. ( 30483986 )	Petrelli F...Tomasello G	2018
12	Identification of Adenosquamous Carcinoma as a Rare Aggressive HER2-negative Subgroup of Esophageal/Gastroesophageal Junction Adenocarcinoma. ( 30516569 )	Jin Z...Yoon HH	2018
13	Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab. ( 30283289 )	Gil-Delgado MA...Khayat D	2018
14	FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1. ( 30120163 )	Fashoyin-Aje L...Pazdur R	2018
15	Significance of blood neutrophil-to-lymphocyte ratio for prognostic stratification of patients with gastroesophageal junction adenocarcinoma in the era of the 8th edition of the American Joint Committee on Cancer (AJCC8) staging. ( 28500616 )	Conway A.M....Mansoor W.	2017
16	Significance of baseline FDG-PET/CT scan as a method of staging regional lymph nodes in patients with operable distal oesophageal or gastroesophageal junction adenocarcinoma. ( 28524708 )	Papaxoinis G....Mansoor W.	2017
17	Health-related quality of life after gastrectomy, esophagectomy, and combined esophagogastrectomy for gastroesophageal junction adenocarcinoma. ( 28852939 )	Kauppila J.H....Lagergren P.	2017
18	HELOISE: Phase IIIb Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose Trastuzumab Regimens Combined With Chemotherapy as First-Line Therapy in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma. ( 28574779 )	Shah M.A....Tabernero J.	2017
19	Efficacy and safety of first-line systemic chemotherapy with epirubicin, cisplatin plus 5-fluorouracil and docetaxel, cisplatin plus 5-fluorouracil regimens in locally advanced inoperable or metastatic gastric or gastroesophageal junction adenocarcinoma: A prospective phase II study from South India. ( 29199662 )	Babu K.G....Rajeev L.K.	2017
20	Preoperative Chemoradiotherapy Versus Perioperative Chemotherapy for Patients With Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma. ( 28424936 )	Anderegg M.C.J....van Hillegersberg R.	2017
21	External beam radiation and high-dose-rate brachytherapy for elderly patients with gastroesophageal junction adenocarcinoma. ( 28951752 )		2017
22	Clinical effectiveness and toxicity of second-line irinotecan in advanced gastric and gastroesophageal junction adenocarcinoma: a single-center observational study. ( 28491144 )		2017
23	HER2 status in Gastric and Gastroesophageal Junction Adenocarcinoma. ( 28588175 )		2017
24	The effect of perioperative chemotherapy for patients with an adenocarcinoma of the gastroesophageal junction: A propensity score matched analysis. ( 27424786 )	Parry K...van Hillegersberg R	2017
25	Targeted therapies for advanced and metastatic adenocarcinoma of the gastroesophageal junction: is there something new? ( 27568322 )	Pasini F...de Manzoni G	2017
26	Explored Risk Factors for Lymph Node Metastasis with Siewert II/III Adenocarcinoma of the Gastroesophageal Junction. ( 28739759 )	Zheng Z...Zhang ZT	2017
27	Surgical approaches to adenocarcinoma of the gastroesophageal junction: the Siewert II conundrum. ( 28803334 )	Brown AM...Palazzo F	2017
28	Management and Reconstruction of a Gastroesophageal Junction Adenocarcinoma Patient Three Years after Pancreaticoduodenectomy: A Surgical Puzzle. ( 27635275 )	Dellaportas D....Davies A.R.	2016
29	Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. ( 26747859 )	Al-Batran S.E....Wilke H.	2016
30	No Survival Difference with Neaodjuvant Chemoradiotherapy Compared with Chemotherapy in Resectable Esophageal and Gastroesophageal Junction Adenocarcinoma: Results from the National Cancer Data Base. ( 27641320 )	Al-Sukhni E....Hochwald S.N.	2016
31	Positioning of second-line treatment for advanced gastric and gastroesophageal junction adenocarcinoma. ( 27774774 )	Pericay C....Imedio E.R.	2016
32	Central nervous system relapse in patients with untreated her2-positive esophageal or gastroesophageal junction adenocarcinoma. ( 27198655 )	Yoon H.H....Sinicrope F.A.	2016
33	Isolated Splenic Metastases of Her2+++ Gastroesophageal Junction Adenocarcinoma. ( 27065846 )	Sigrand J....Raoul J.L.	2016
34	Dysphagia is not a Valuable Indicator of Tumor Response after Preoperative Chemotherapy for R0 Resected Patients with Adenocarcinoma of the Gastroesophageal Junction. ( 26250355 )	Strandby RB...Achiam MP	2016
35	Staging of adenocarcinoma of the gastroesophageal junction. ( 26777127 )	Parry K...van Hillegersberg R	2016
36	Unintentional Long-Term Esophageal Stenting due to a Complete Response in a Patient with Stage UICC IV Adenocarcinoma of the Gastroesophageal Junction. ( 27462189 )	Paeschke A...Daum S	2016
37	Patient preferences for palliative treatment of locally advanced or metastatic gastric cancer and adenocarcinoma of the gastroesophageal junction: a choice-based conjoint analysis study from Germany. ( 27923357 )	Hofheinz R...Br?ck P	2016
38	Comparison of efficacy and safety of first-line palliative chemotherapy with EOX and mDCF regimens in patients with locally advanced inoperable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma: a randomized phase 3 trial. ( 26354521 )	Ochenduszko S....Krzemieniecki K.	2015
39	Survey of Her2-neu Expression and its Correlation with Histology of Gastric Carcinoma and Gastroesophageal Junction Adenocarcinoma. ( 26625793 )	Madani S.H....Amirifard N.	2015
40	Comparisons of Clinical Outcomes and Prognoses in Patients With Gastroesophageal Junction Adenocarcinoma, by Transthoracic and Transabdominal Hiatal Approaches: A Teaching Hospital Retrospective Cohort Study. ( 26683954 )	Zhou J....Zhou Y.	2015
41	Incidence of brain metastases in HER2+ gastric or gastroesophageal junction adenocarcinoma. ( 25753188 )	Blay C....Edeline J.	2015
42	NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors. ( 25530271 )	Schulz C...Heinemann V	2015
43	Combined neutron brachytherapy with external beam radiation in patients with inoperable gastroesophageal junction adenocarcinoma. ( 25296599 )	Wang Q....Wan X.	2014
44	The safety and usefulness of neutron brachytherapy and external beam radiation in the treatment of patients with gastroesophageal junction adenocarcinoma with or without chemotherapy. ( 24774780 )		2014
45	Personalizing risk stratification by addition of PAK1 expression to TNM staging: Improving the accuracy of clinical decision for gastroesophageal junction adenocarcinoma. ( 25159681 )		2014
46	Gastroesophageal junction adenocarcinoma displays abnormalities in homologous recombination and nucleotide excision repair. ( 28210138 )	Dewalt RI...Jalal SI	2014
47	Biweekly docetaxel, fluorouracil, leucovorin, oxaliplatin (TEF) as first-line treatment for advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: safety and efficacy in a multicenter cohort. ( 23739764 )	Pernot S...Taieb J	2014
48	Incidence of microscopically positive proximal margins in adenocarcinoma of the gastroesophageal junction. ( 24505353 )	Gao F...Shen L	2014
49	Phase II trial of bortezomib alone or in combination with irinotecan in patients with adenocarcinoma of the gastroesophageal junction or stomach. ( 24526575 )	Ocean AJ...Lane ME	2014
50	The role of radiation therapy for resectable adenocarcinoma of the gastroesophageal junction. ( 24729606 )	Al-Batran SE	2014

Sources

Genes for Gastroesophageal Junction Adenocarcinoma

Genes related to Gastroesophageal Junction Adenocarcinoma (0 elite genes):

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	ERBB2	Erb-B2 Receptor Tyrosine Kinase 2	Protein Coding	23.72	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
2	MTA3	Metastasis Associated 1 Family Member 3	Protein Coding	22.14	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
3	SNAI1	Snail Family Transcriptional Repressor 1	Protein Coding	20.11	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
4	IL1B	Interleukin 1 Beta	Protein Coding	16.95	GeneCards inferred via : Publications (show sections)
5	TLR9	Toll Like Receptor 9	Protein Coding	16.19	DISEASES inferred ¹⁵ ¹⁵
6	GUCY2C	Guanylate Cyclase 2C	Protein Coding	15.21	DISEASES inferred ¹⁵

Sources

Variations for Gastroesophageal Junction Adenocarcinoma

Sources

Expression for Gastroesophageal Junction Adenocarcinoma

Search GEO for disease gene expression data for Gastroesophageal Junction Adenocarcinoma.

Sources

Pathways for Gastroesophageal Junction Adenocarcinoma

Pathways related to Gastroesophageal Junction Adenocarcinoma according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Dendritic Cells Developmental Lineage Pathway ⁶⁵	11.19	IL1B TLR9
2	Adherens junction ³⁷	11.11	ERBB2 SNAI1
3	MAPK Pathway ⁷² Show member pathways Toll-like Receptor Pathway ⁷²	10.89	ERBB2 IL1B TLR9
4	Malaria ³⁷	10.85	IL1B TLR9
5	African trypanosomiasis ³⁷	10.5	IL1B TLR9

Sources

GO Terms for Gastroesophageal Junction Adenocarcinoma

Biological processes related to Gastroesophageal Junction Adenocarcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of gene expression	GO:0010628	9.61	ERBB2 IL1B TLR9
2	wound healing	GO:0042060	9.48	ERBB2 IL1B
3	positive regulation of JNK cascade	GO:0046330	9.46	IL1B TLR9
4	positive regulation of interleukin-6 production	GO:0032755	9.4	IL1B TLR9
5	positive regulation of NIK/NF-kappaB signaling	GO:1901224	9.37	IL1B TLR9
6	positive regulation of epithelial to mesenchymal transition	GO:0010718	9.32	IL1B SNAI1
7	positive regulation of JUN kinase activity	GO:0043507	9.26	IL1B TLR9
8	positive regulation of interleukin-8 production	GO:0032757	9.16	IL1B TLR9
9	regulation of ERK1 and ERK2 cascade	GO:0070372	8.96	ERBB2 IL1B
10	positive regulation of granulocyte macrophage colony-stimulating factor production	GO:0032725	8.62	IL1B TLR9

Molecular functions related to Gastroesophageal Junction Adenocarcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	interleukin-1 receptor binding	GO:0005149	8.62	IL1B TLR9

Sources

Sources for Gastroesophageal Junction Adenocarcinoma

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ ExPASy

¹⁸ FDA Approved Drugs

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ SNOMED-CT via Orphanet

⁷¹ TGDB

⁷² Tocris

⁷³ UMLS

⁷⁴ UMLS via Orphanet

⁷⁵ UniProtKB/Swiss-Prot

⁷⁶ Wikipedia